What Food, Pharma and Nutraceutical Buyers Must Know

2026 EU Additive Amendments: What Citrate Buyers Should Know Commission Regulations (EU) 2026/189 and 2026/196 entered into force on 18 February 2026. Regulation 2026/196 introduces mandatory microbiological criteria for hydrocolloids and E1450 used in infant foods and FSMP. Citrates (E331 to E333) are not directly amended, but the regulation establishes a clear industry direction that progressive buyers are already applying to all additive suppliers including citrate manufacturers.

The European Citrate Market: Size, Scope and Stakes

Europe is the world’s largest single market for citric acid and citrate salts, accounting for approximately 45 percent of global market share. The continent’s strict regulatory framework, high food safety standards, and advanced pharmaceutical manufacturing base drive consistent, high-value demand for quality-certified ingredients. For Asian manufacturers with WHO-GMP credentials, the EU represents the most rewarding export destination in the world.
Yet that same regulatory rigour creates significant compliance complexity. Procurement managers at European food, pharma, and nutraceutical companies must navigate a layered framework of Union legislation, pharmacopoeial standards, and sector-specific guidance documents. The 2026 amendments to the food additive regulations represent the most consequential update to this framework in several years.

The EU pharmaceutical excipient market is particularly important for citrate suppliers. Sodium citrate, potassium citrate, and calcium citrate are widely used across tablet buffering, parenteral formulations, oral liquids, and lyophilised products. Demand is further buoyed by the electrolyte supplement boom, with organic mineral salts commanding a premium in functional foods and sports nutrition formats now mainstream across Germany, the Netherlands, France, and the UK.

Why the EU Just Updated Its Food Additive Rules

The European Food Safety Authority (EFSA) has been conducting a systematic re-evaluation of all food additives currently authorised under Regulation (EC) No 1333/2008 since 2010. This programme, mandated by Regulation (EU) No. 257/2010, has methodically reviewed each additive against updated scientific evidence, applying modern risk assessment methodology to specifications that in some cases had not been scrutinized since the 1990s.

The January 2026 amendments represent the outcome of recent EFSA re-evaluations specifically focused on product categories consumed by vulnerable populations. Scientific panels concluded that while the widely used citrate salts (E331 to E333) remain safe for general food applications, specific applications in infant formula, follow-on formula, processed cereal-based foods, and Foods for Special Medical Purposes warranted tightened microbiological specifications and updated purity criteria. The commission acted swiftly to translate those scientific opinions into binding legislation.

This is not a niche regulatory tweak. Any company manufacturing, importing, or using food-grade citrate salts in the EU must review whether their current supply arrangements remain compliant. The August 2026 deadline is only months away.

What Changed: The Two Key Regulations

Two commission regulations were published together on 29 January 2026. They work in concert: one updates the authorised uses list, the other updates the technical specifications that define the identity and purity of the additives themselves.

The Microbiological Safety Requirement in Detail

The headline change under Regulation (EU) 2026/196 is the mandatory microbiological testing requirement for food additives destined for vulnerable population product categories. The specific criteria introduced are:

• Absence of Salmonella in 25g of the additive per batch
• Absence of Cronobacter in 10g of the additive per batch

Cronobacter sakazakii is a particular concern in infant nutrition due to the organism’s association with severe neonatal meningitis and necrotising enterocolitis. The inclusion of Cronobacter as a mandatory test criterion specifically for additives destined for infant formula reflects the highest level of regulatory caution and aligns EU food additive standards with the microbiological criteria already applied to infant formula base ingredients.

For suppliers, this means microbiological testing must now be performed and documented on a per-batch basis where citrate salts are sold into infant food or FSMP applications. Generic annual certificates of analysis are no longer sufficient for these product categories.

Revised Purity Specifications: What to Expect

Beyond microbiological criteria, the amended Regulation (EU) No 231/2012 updates the technical specifications for a number of additives, including citrates. Key areas of revision include limits on heavy metal impurities, specifications for residual solvents where relevant, and more granular identity testing requirements aligned with current pharmacopoeial standards. European buyers should request updated CoA templates from their suppliers that explicitly cross-reference the post-2026 specification requirements.

Compliance Timeline

Understanding the phased implementation schedule is critical for procurement teams planning reformulation or supplier qualification activities:

Which Citrate Applications Are Affected?

The impact of the 2026 amendments varies depending on the citrate salt, its grade, and its intended application. The table below provides a rapid reference for procurement and regulatory affairs teams:

Industry-by-Industry Compliance Guide

The 2026 amendments touch different sectors with different degrees of urgency. Here is a sector-specific breakdown of what compliance means in practice.

Infant Nutrition Manufacturers

Infant formula and follow-on formula manufacturers face the most immediate and stringent requirements. The new Cronobacter and Salmonella criteria apply directly to the citrate salts used as buffers and pH regulators in these products. Manufacturers should:

• Audit current citrate supplier CoA templates against post-February 2026 specifications
• Request per-batch microbiological certificates for Salmonella and Cronobacter from all citrate suppliers
• Update quality agreements and supplier qualification documentation to reflect new criteria
• Review product labels and technical dossiers if reformulation is required
• Confirm that all citrates used in powdered infant formula comply by the August 2026 deadline

Pharmaceutical Excipient Buyers

Pharmaceutical manufacturers and contract development organisations (CDOs) using citrate salts as excipients in EU-marketed medicines need to verify whether their current pharmaceutical-grade citrate suppliers meet the updated Regulation (EU) No 231/2012 specifications. Key actions include:

• Verify supplier Ph. Eur. monograph compliance against the 2026 revised specifications
• Request updated pharmaceutical impurity profiles and residual solvent declarations
• Confirm WHO-GMP or EU GMP certification is current and listed in EudraGMDP where applicable
• Review existing Certificates of Suitability (CEP) from EDQM if applicable to the citrate grade used
• Update Drug Master File (DMF) excipient documentation if regulatory submissions reference the old specifications

Food and Beverage Manufacturers

For mainstream food and beverage applications, the 2026 amendments have limited direct impact unless the products target infant or paediatric consumers. However, this is a good opportunity for procurement teams to future-proof their supplier documentation. Recommended actions:

• Confirm current CoAs reference EU No 231/2012 as amended in 2026
• Obtain updated supplier declarations of compliance with Regulation (EC) No 1333/2008
• Request allergen, GMO, and country of origin declarations if not already on file
• Consider requesting BSE/TSE declarations even where not currently required, as a supply chain resilience measure

Nutraceutical and Dietary Supplement Manufacturers

The nutraceutical sector sits at the intersection of food and pharmaceutical regulations. Citrate mineral salts (potassium citrate, magnesium citrate, calcium citrate, zinc citrate) are central to electrolyte, bone health, and cognitive supplement formulations. Companies selling into the EU market should ensure:

• Citrate salts used in products for children or infants meet the new microbiological criteria
• Mineral citrate grades meet EU FCC, Ph. Eur., or applicable national pharmacopoeial standards
• Product notifications filed under the relevant member state frameworks remain consistent with supplier documentation
• Clean-label and traceability claims are backed by full batch documentation from the citrate supplier

Foods for Special Medical Purposes (FSMP) Producers

FSMP producers face a dual burden: the new Regulation (EU) 2026/189 directly affects authorised uses within this category, while Regulation (EU) 2026/196 imposes the microbiological criteria that also apply to infant foods. Companies manufacturing tube feeds, oral nutritional supplements, and metabolic disease products should treat this as a high-priority compliance event and engage their regulatory affairs teams and citrate suppliers simultaneously.

Documentation Checklist for EU Citrate Buyers

When sourcing citrates from any supplier for the European market post-February 2026, request and verify the following documents. This checklist applies to every onboarding and annual supplier review:

Sourcing Strategy: European vs. International Citrate Suppliers

A recurring question among EU procurement managers is whether to source citrates from European manufacturers or from qualified international suppliers. The 2026 regulatory changes do not create any preference for European origin in the legislation. What matters is product quality, documentation integrity, and the supplier’s ability to meet the technical specifications. This section examines both options objectively.

The Case for European Manufacturers

• Shorter lead times – Domestic or intra-EU sourcing reduces transit time and simplifies logistics planning
• Currency stability – EUR-denominated pricing eliminates exchange rate exposure for EU buyers
• Audit accessibility – Facility audits are easier to schedule and less costly to execute
• Regulatory proximity – Some European suppliers have long-standing relationships with national competent authorities
• Sustainability credentials – Several European producers use bio-based fermentation processes from regional agricultural feedstocks

The Case for International WHO-GMP Certified Manufacturers

• Production scale – Asian manufacturers typically operate at significantly higher volumes, enabling supply chain continuity for large-scale buyers
• Competitive pricing – Lower input and labour costs translate to better economics, particularly for commodity-grade applications
• Documentation depth – Leading WHO-GMP certified manufacturers in India produce documentation packages that match or exceed European standards
• Grade breadth – Large-scale producers offer the full citrate range (food, pharma, Ph. Eur., USP, FCC) from a single source, simplifying supplier management
• Regulatory equivalence – WHO-GMP certification is formally recognised across the EU for food additive imports; EudraGMDP listings are achievable for pharmaceutical-grade products

Understanding EU GMP vs. WHO-GMP: What Buyers Should Know

Confusion between EU GMP and WHO-GMP is common in procurement teams, particularly where the same product may be used across both food and pharmaceutical applications. The distinction matters for qualification and documentation purposes.

For food-grade citrate additives (E331, E332, E333) used in standard food manufacturing, WHO-GMP certification combined with FSSC 22000 or ISO 22000 is sufficient for import and use in the EU. The product simply needs to meet the technical specifications of Regulation (EU) No 231/2012 as amended and be used within the authorised categories and limits of Regulation (EC) No 1333/2008.

For pharmaceutical excipients used in EU-licensed medicinal products, EU GMP Part II alignment (based on the IPEC-PIC/S Good Manufacturing Guide) is increasingly expected by marketing authorisation holders during supplier qualification audits. An EDQM Certificate of Suitability (CEP) provides the highest level of assurance for Ph. Eur. monographed excipients and streamlines the regulatory file for the finished medicine. Daffodil Pharmachem’s WHO-GMP certification covers our pharmaceutical excipient production environment, and we support EU GMP audit requests with full site master files and quality agreements.

How Daffodil Pharmachem Supports EU Compliance

As Asia’s largest WHO-GMP certified citrate manufacturer, Daffodil Pharmachem has built its EU export programme around the documentation standards and technical specifications that European buyers require. Our DaffoCitra brand covers the complete range of citrate salts produced to Ph. Eur., USP, BP, and FCC standards, with batch-level traceability from raw material sourcing through finished product release and export documentation.

The Daffodil Pharmachem Portfolio

Our Standard EU Documentation Package

• Batch-specific Certificate of Analysis (CoA) with full Ph. Eur. / FCC parameter set
• Microbiological report: Total Plate Count, yeast and mould, Salmonella, E. coli, Cronobacter spp. on request
• WHO-GMP compliance certificate (current)
• BSE/TSE declaration
• Allergen and GMO declaration
• EU-format Safety Data Sheet (REACH compliant)
• Halal and Kosher certificates (available for all grades)
• REACH-compliant packaging and labelling documentation
• Quality Agreement templates for pharmaceutical and food-grade supply
• Site Master File excerpt available for EU GMP audit support

Step-by-Step Compliance Action Plan for EU Buyers

The following action plan is designed for regulatory affairs and procurement professionals who need to confirm supply chain compliance with the 2026 amendments before the August 2026 deadline.

EU Country Market Spotlights: Priority Destinations for Citrate Exports

Three EU markets stand out as the highest-priority destinations for citrate salt exports from WHO-GMP certified manufacturers. Each has distinct characteristics in terms of buyer profile, regulatory stringency, and procurement culture.

Need EU-Compliant Citrates for Your Supply Chain?
Our team can prepare a complete documentation package tailored to your EU regulatory requirements: CoA, GMP certificates, microbiological reports, BSE/TSE declarations, and more.
Contact: info@daffodilpharma.com | www.daffodilpharma.com